Physician profile
Amber L Simson
NPI 1245584309
$481.24
in general payments reported to CMS, 2019-2025
15 companies · $71.90 in 2025
The $71.90 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $173 · 2023: $115 · 2024: $122 · 2025: $71.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $63.25 | 2023-2024 | Lucemyra, Zimhi |
| Cranial Technologies, INC | $61.60 | 2022-2025 | Doc Band |
| Alkermes, INC. | $52.22 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Glaxosmithkline, LLC. | $50.66 | 2022-2023 | Shingrix |
| Indivior INC. | $48.77 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.94 | 2022 | |
| Gilead Sciences, INC. | $25.47 | 2022 | |
| Dexcom, INC. | $24.94 | 2024 | Dexcom G6 Transmitter |
| Braeburn INC. | $21.11 | 2024 | Brixadi |
| Lilly USA, LLC | $20.68 | 2025 | Mounjaro |
| Merck Sharp & Dohme LLC | $20.67 | 2023 | Proquad, Vaxelis, Vaxneuvance |
| Seqirus USA INC | $19.42 | 2025 | Flucelvax, Fluad |
| Phathom Pharmaceuticals, INC. | $18.38 | 2024 | Voquezna |
| Abbvie INC. | $13.99 | 2025 | |
| Novo Nordisk INC | $13.14 | 2024 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Simson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.